RxDoctor Payments Data

Todd Fennell, MD

Internal Medicine · Greer, SCNPI 1083639884

Payments from drug & device makers

$11,076in general payments, 2019–2025

Across 736 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$935
  • Pfizer$747
  • Lilly USA, LLC$740
  • Amgen$682
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$11,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,076 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$221,580
Medicare patients
320
Services billed
3,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$137,642
MounjaroTirzepatide41$66,267
JardianceEmpagliflozin42$51,355
EliquisApixaban33$41,787
Tresiba Flextouch U-200Insulin Degludec33$23,971
XareltoRivaroxaban21$20,619
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,310
TrulicityDulaglutide14$12,879
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,558
Repatha SureclickEvolocumab17$10,208
MyrbetriqMirabegron12$9,787
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,678
Tresiba Flextouch U-100Insulin Degludec12$8,868
Insulin Degludec Pen (U-200)Insulin Degludec19$7,740
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,647$137,642104 claims
Lilly USA, LLCMounjaro, Trulicity$740$79,14655 claims
Boehringer IngelheimJardiance$395$51,35542 claims
PfizerEliquis$747$41,78733 claims
Johnson & JohnsonXarelto$162$20,61921 claims
GSKTrelegy Ellipta, Anoro Ellipta$404$20,03036 claims
AstraZenecaBreztri Aerosphere$935$10,55815 claims
Astellas Pharma US IncMyrbetriq$394$9,78712 claims
MerckJanumet$62$5,91611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →